A CD47‐targeting antibody used in combination with the anti‐CD20 antibody Rituximab in patients with relapsed or refractory DLBCL or FL yielded complete response in about 36% of patients.158, 160. Here, CD47 is linked to diffuse large B-cell lymphoma.